

Specialty Guideline Management

Egrifta

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Egrifta SV	tesamorelin acetate
Egrifta WR	tesamorelin acetate

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications^{1,2}

Egrifta is indicated for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected adult patients with lipodystrophy.

Limitations of Use

- Long-term cardiovascular safety of Egrifta has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue.
- Egrifta is not indicated for weight loss management as it has a weight neutral effect.
- There are no data to support improved compliance with antiretroviral therapies in HIV-positive patients taking Egrifta.

All other indications are considered experimental/investigational and not medically necessary.

Exclusions

Coverage will not be provided for weight loss.

Prescriber Specialties

This medication must be prescribed by or in consultation with an infectious disease specialist.

Coverage Criteria

Reduction of Excess Abdominal Fat in Human Immunodeficiency Virus (HIV)-Infected Patients with Lipodystrophy^{1,2}

Authorization of 6 months may be granted for members who meet all of the following criteria:

- Member has HIV infection and lipodystrophy.
- Member is currently receiving antiretroviral therapy.
- The requested medication will be used to reduce excess abdominal fat.

Continuation of Therapy¹⁻³

Authorization of 6 months may be granted for continued treatment in members requesting reauthorization for reduction of excess abdominal fat when all of the following criteria are met:

- Member has HIV infection and lipodystrophy.
- Member is currently receiving antiretroviral therapy.
- Member has demonstrated a clear clinical improvement from baseline that is supported by waist circumference measurement or computed tomography (CT) scan.

References

1. Egrifta SV [package insert]. Montreal, Québec, Canada: Theratechnologies Inc.; December 2024.
2. Egrifta WR [package insert]. Montreal, Québec: Theratechnologies Inc.; March 2025.
3. Brown TT. Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab. 2008;93(8):2937-2945.